First-Line Immunosuppressive Therapies for Acquired Hemophilia A: A 25-year Cohort Experience and Network Meta-Analysis Short title: First-Line Immunosuppressive Therapies in AHA

Completed

• Conditions: Acquired hemophilia; Acquired hemophilia A; Complete remission; Immunosuppressive treatment; Relapse

• Registration Number: TCTR20240405005
• Lead Sponsor: /A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-02-01
• Study Start: 2024-04-05
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

Newly diagnosed acquired hemophilia patients age 18 years old and above

Exclusion Criteria

Congenital hemophilia with inhibitor

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complete remission rate Time at diagnosis to time of CR (normalization of factor VIII (more than 50%), undetectable inhibitor, and immunosuppression stopped without relapse) Percentage

Secondary Outcome Measures

Name	Time	Method
Relapse rate Time of CR to time of relapse ( the reappearance of the FVIII inhibitor after a patient achieved CR, and with or without bleeding symptoms) Percentage,Time to CR Time to diagnosis to time to CR Months